- Home
- ZDGE vs ACRV Comparison
ZDGE vs ACRV Comparison
Compare ZDGE & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZDGE
- ACRV
- Stock Information
- Founded
- ZDGE 2008
- ACRV 2018
- Country
- ZDGE United States
- ACRV United States
- Employees
- ZDGE N/A
- ACRV N/A
- Industry
- ZDGE Computer Software: Prepackaged Software
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- ZDGE Technology
- ACRV Health Care
- Exchange
- ZDGE Nasdaq
- ACRV Nasdaq
- Market Cap
- ZDGE 39.9M
- ACRV 47.8M
- IPO Year
- ZDGE N/A
- ACRV 2022
- Fundamental
- Price
- ZDGE $3.09
- ACRV $1.52
- Analyst Decision
- ZDGE
- ACRV Buy
- Analyst Count
- ZDGE 0
- ACRV 7
- Target Price
- ZDGE N/A
- ACRV $17.40
- AVG Volume (30 Days)
- ZDGE 40.5K
- ACRV 3.4M
- Earning Date
- ZDGE 10-28-2025
- ACRV 11-12-2025
- Dividend Yield
- ZDGE N/A
- ACRV N/A
- EPS Growth
- ZDGE N/A
- ACRV N/A
- EPS
- ZDGE N/A
- ACRV N/A
- Revenue
- ZDGE $29,511,000.00
- ACRV N/A
- Revenue This Year
- ZDGE N/A
- ACRV N/A
- Revenue Next Year
- ZDGE $2.95
- ACRV $805.34
- P/E Ratio
- ZDGE N/A
- ACRV N/A
- Revenue Growth
- ZDGE 1.27
- ACRV N/A
- 52 Week Low
- ZDGE $1.73
- ACRV $1.05
- 52 Week High
- ZDGE $4.89
- ACRV $10.00
- Technical
- Relative Strength Index (RSI)
- ZDGE 44.78
- ACRV 56.53
- Support Level
- ZDGE $2.91
- ACRV $1.30
- Resistance Level
- ZDGE $3.25
- ACRV $2.67
- Average True Range (ATR)
- ZDGE 0.15
- ACRV 0.19
- MACD
- ZDGE 0.03
- ACRV 0.02
- Stochastic Oscillator
- ZDGE 57.89
- ACRV 16.06
About ZDGE Zedge Inc. Class B
Zedge Inc provides content distribution platforms. Its content platform enables consumers to personalize their mobile devices with free, high-quality ringtones, wallpapers, home screen app icons, widgets and notification sounds as well as paint, a generative AI wallpaper maker, GuruShots, a skill-based photo challenge game, and Emojipedia. The company also launched a Zedge app. It has two reportable segments, which are the Zedge Marketplace and GuruShots.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.